Indaptus Therapeutics appoints David Natan to board and audit committee

Indaptus Therapeutics, Inc.

Board increased from 8 to 9 members; David Natan appointed as Class II director until 2026 annual meeting.
Natan replaces Avraham Ben-Tzvi as Audit Committee member; Ben-Tzvi to become paid consultant while remaining on board.
Natan was designated by David E. Lazar under securities purchase agreement dated December 22, 2025.
Natan is CPA and CEO of Natan & Associates; also serves on boards of Sunshine Biopharma and FIEE.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.